Covered recipient · General Payments record
RACHEL ELIZABETH RAAB
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$910.03
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $230.47 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| TerSera Therapeutics LLC | $70.62 | 1 |
| Acerta Pharma LLC | $42.67 | 2 |
| ABBVIE INC. | $24.26 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $21.43 | 1 |
| Merck Sharp & Dohme Corporation | $21.21 | 1 |
| Gilead Sciences, Inc. | $19.45 | 1 |
| Janssen Biotech, Inc. | $15.84 | 1 |
| TAIHO ONCOLOGY, INC. | $14.99 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.26 | 12/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105340971 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.79 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105599185 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.88 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104740423 | CMS |
| Gilead Sciences, Inc. | $19.45 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133795755 | CMS |
| Janssen Biotech, Inc. | $15.84 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078816494 | CMS |
| Merck Sharp & Dohme LLC | $21.21 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141827602 | CMS |
| Novartis Pharmaceuticals Corporation | $21.43 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087252273 | CMS |
| TAIHO ONCOLOGY, INC. | $14.99 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137941396 | CMS |
| TerSera Therapeutics LLC | $70.62 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144717669 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.